Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.44 |
| ▸ | CES1 | P23141 | 5/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28471288 | 1.00 | FAAH (0.44) | FAAHCES1CES2MEN1KMT2A | |
| Phosphoric Acid SCHEMBL28324933 | 1.00 | FAAH (0.44) | FAAHCES1CES2MEN1KMT2A | |
| Phosphoric Acid SCHEMBL7807537 | 1.00 | FAAH (0.44) | FAAHCES1CES2MEN1KMT2A | |
| Octane SCHEMBL16440085 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2016841 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1517931 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345503 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9503018 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL14989523 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1340804 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045525-B1 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | claimed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | claimed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | claimed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | claimed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | claimed |
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-04-21 | — | — | US | disclosed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | disclosed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | FAAH 4171/4885CES1 998/4885CES2 1639/4885 |
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | FAAH 4171/4885CES1 998/4885CES2 1639/4885 |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | TYMP, PNP, HPRT1 | FAAH 4171/4885CES1 998/4885CES2 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.